FDA Approves Xdemvy for Demodex Blepharitis
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
FRIDAY, July 28, 2023 -- The U.S. Food and Drug Administration has approved Xdemvy (lotilaner ophthalmic solution) 0.25 percent for the treatment of Demodex blepharitis, caused by Demodex mites.
The approval was based on results from two randomized, vehicle-controlled studies (Saturn-1 and Saturn-2) in which 833 patients were randomly assigned (1:1) to either Xdemvy or vehicle twice daily in each eye for six weeks. The results of the trials showed significant improvement in eyelids (reduction of collarettes, the pathognomonic sign of the disease, to no more than two collarettes per upper lid) in each study by day 43. Some patients saw improvement as early as two weeks. The end points of mite eradication (mite density of zero mites per lash) and erythema cure (grade 0) were significantly improved at day 43 in both studies.
Xdemvy was generally safe and well tolerated. The most common ocular adverse reactions included instillation site stinging and burning (reported in 10 percent of patients), as well as chalazion/hordeolum (stye) and punctate keratitis (less than 2 percent of patients).
"After years of seeing Demodex blepharitis in my practice without an effective way to target the root cause of the disease, I'm so pleased to have a new treatment to offer my patients," ophthalmologist Christopher Starr, M.D., from Weill Cornell Medicine and New York Presbyterian Hospital in New York City, said in a statement. "This new medicine is a positive step forward for the treatment of this disease in many patients who have been struggling for years."
Approval of Xdemvy was granted to Tarsus Pharmaceuticals.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
GLP-1 Drugs Ozempic, Wegovy Linked to Rare Blinding Condition
WEDNESDAY, July 3, 2024 -- Trendy weight-loss drugs appear to increase the risk of a rare and potentially blinding eye condition, a new study warns. People with diabetes...
Protect Your Eyes From Summer's Dangers
SATURDAY, June 15, 2024 -- Summertime is primetime for the great outdoors, but that can mean new hazards for your eyes, one expert warned. Simple steps can help cut the risk...
Robotic Procedure Helps Treat Macular Degeneration
THURSDAY, June 12, 2024 -- Robot-guided radiation therapy can improve treatment for age-related macular degeneration, the leading cause of vision loss and blindness among American...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
